WallStreetZenWallStreetZen

NASDAQ: SXTC
China Sxt Pharmaceuticals Inc Earnings & Revenue

OverviewEarnings
DividendOwnership

SXTC past revenue growth

How has SXTC's revenue growth performed historically?
Company
-91.18%
Industry
10.18%
Market
17.2%
SXTC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SXTC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SXTC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SXTC earnings and revenue history

Current Revenue
$29.9k
Current Earnings
-$14.1M
Current Profit Margin
-47,248.6%

SXTC Return on Equity

Current Company
-141.6%
Current Industry
10.7%
Current Market
-8.4%
SXTC's Return on Equity (-141.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SXTC announces earnings.

SXTC Return on Assets

Current Company
-76.9%
Current Industry
2.9%
SXTC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SXTC Return on Capital Employed

Current Company
-254.41%
Current Industry
5.5%
SXTC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SXTC vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SXTC$29.92k-$13.36M-$14.14M-27.77%N/A
SBFM$24.09M-$3.82M-$4.51M+481.16%N/A
AKAN$3.94M-$10.41M-$14.94M+3,466.29%N/A
PRFX$0.00-$9.57M-$9.34MN/AN/A
LSDI$16.73k-$9.75M-$11.30MN/AN/A
View Top Pharmaceutical Stocks

China Sxt Pharmaceuticals Earnings & Revenue FAQ

What were SXTC's earnings last quarter?

China Sxt Pharmaceuticals (NASDAQ: SXTC) reported Q3 2023 earnings per share (EPS) of N/A, up N/A year over year. Total China Sxt Pharmaceuticals earnings for the quarter were N/A. In the same quarter last year, China Sxt Pharmaceuticals's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy China Sxt Pharmaceuticals stock.

What was SXTC's earnings growth in the past year?

As of Q2 2024, China Sxt Pharmaceuticals's earnings has grown year over year. China Sxt Pharmaceuticals's earnings in the past year totalled -$14.14 million.

What was SXTC's revenue last quarter?

China Sxt Pharmaceuticals (NASDAQ: SXTC) reported Q3 2023 revenue of N/A up N/A year over year. In the same quarter last year, China Sxt Pharmaceuticals's revenue was N/A.

What was SXTC's revenue growth in the past year?

As of Q2 2024, China Sxt Pharmaceuticals's revenue has grown -91.18% year over year. This is 101.36 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.18%. China Sxt Pharmaceuticals's revenue in the past year totalled $29.92 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.